CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells

Immunotherapies, such as chimeric antigen receptor (CAR) modified T cells and antibody-drug conjugates (ADCs), have revolutionized the treatment of cancer, especially of lymphoid malignancies. The application of targeted immunotherapy to patients with acute myeloid leukemia (AML) has been limited in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Liu, Yi (VerfasserIn) , Wang, Sanmei (VerfasserIn) , Schubert, Maria-Luisa (VerfasserIn) , Lauk, Annika (VerfasserIn) , Yao, Hao (VerfasserIn) , Blank, Maximilian Felix (VerfasserIn) , Cui, Chunhong (VerfasserIn) , Janssen, Maike (VerfasserIn) , Schmidt, Christina (VerfasserIn) , Göllner, Stefanie (VerfasserIn) , Kleist, Christian (VerfasserIn) , Zhou, Fengbiao (VerfasserIn) , Rahfeld, Jens-Ulrich (VerfasserIn) , Sauer, Tim (VerfasserIn) , Schmitt, Michael (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: International journal of cancer
Year: 2022, Jahrgang: 150, Heft: 7, Pages: 1141-1155
ISSN:1097-0215
DOI:10.1002/ijc.33865
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.33865
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33865
Volltext
Verfasserangaben:Yi Liu, Sanmei Wang, Maria-Luisa Schubert, Annika Lauk, Hao Yao, Maximilian Felix Blank, Chunhong Cui, Maike Janssen, Christina Schmidt, Stefanie Göllner, Christian Kleist, Fengbiao Zhou, Jens-Ulrich Rahfeld, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow

MARC

LEADER 00000caa a2200000 c 4500
001 1843457741
003 DE-627
005 20230706224235.0
007 cr uuu---uuuuu
008 230424s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/ijc.33865  |2 doi 
035 |a (DE-627)1843457741 
035 |a (DE-599)KXP1843457741 
035 |a (OCoLC)1389533815 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Liu, Yi  |e VerfasserIn  |0 (DE-588)1164192132  |0 (DE-627)1028654979  |0 (DE-576)508429986  |4 aut 
245 1 0 |a CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells  |c Yi Liu, Sanmei Wang, Maria-Luisa Schubert, Annika Lauk, Hao Yao, Maximilian Felix Blank, Chunhong Cui, Maike Janssen, Christina Schmidt, Stefanie Göllner, Christian Kleist, Fengbiao Zhou, Jens-Ulrich Rahfeld, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow 
264 1 |c 2022 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First published: 11 November 2021 
500 |a Gesehen am 24.04.2023 
520 |a Immunotherapies, such as chimeric antigen receptor (CAR) modified T cells and antibody-drug conjugates (ADCs), have revolutionized the treatment of cancer, especially of lymphoid malignancies. The application of targeted immunotherapy to patients with acute myeloid leukemia (AML) has been limited in particular by the lack of a tumor-specific target antigen. Gemtuzumab ozogamicin (GO), an ADC targeting CD33, is the only approved immunotherapeutic agent in AML. In our study, we introduce a CD33-directed third-generation CAR T-cell product (3G.CAR33-T) for the treatment of patients with AML. 3G.CAR33-T cells could be expanded up to the end-of-culture, that is, 17 days after transduction, and displayed significant cytokine secretion and robust cytotoxic activity when incubated with CD33-positive cells including cell lines, drug-resistant cells, primary blasts as well as normal hematopoietic stem and progenitor cells (HSPCs). When compared to second-generation CAR33-T cells, 3G.CAR33-T cells exhibited higher viability, increased proliferation and stronger cytotoxicity. Also, GO exerted strong antileukemia activity against CD33-positive AML cells. Upon genomic deletion of CD33 in HSPCs, 3G.CAR33-T cells and GO preferentially killed wildtype leukemia cells, while sparing CD33-deficient HSPCs. Our data provide evidence for the applicability of CD33-targeted immunotherapies in AML and its potential implementation in CD33 genome-edited stem cell transplantation approaches. 
650 4 |a acute myeloid leukemia 
650 4 |a CD33 
650 4 |a CD33-editing 
650 4 |a chimeric antigen receptor T cells 
650 4 |a CRISPR/Cas9 
650 4 |a gemtuzumab ozogamicin 
650 4 |a hematopoietic stem and progenitor cells 
650 4 |a third generation CAR T cells 
700 1 |a Wang, Sanmei  |e VerfasserIn  |4 aut 
700 1 |a Schubert, Maria-Luisa  |d 1982-  |e VerfasserIn  |0 (DE-588)1147867631  |0 (DE-627)1007273801  |0 (DE-576)49608089X  |4 aut 
700 1 |a Lauk, Annika  |d 1997-  |e VerfasserIn  |0 (DE-588)1286858496  |0 (DE-627)1843456079  |4 aut 
700 1 |a Yao, Hao  |d 1992-  |e VerfasserIn  |0 (DE-588)1286858801  |0 (DE-627)1843456370  |4 aut 
700 1 |a Blank, Maximilian Felix  |d 1990-  |e VerfasserIn  |0 (DE-588)1148021574  |0 (DE-627)1007497351  |0 (DE-576)496147528  |4 aut 
700 1 |a Cui, Chunhong  |e VerfasserIn  |4 aut 
700 1 |a Janssen, Maike  |e VerfasserIn  |0 (DE-588)1190667665  |0 (DE-627)166922645X  |4 aut 
700 1 |a Schmidt, Christina  |d 1997-  |e VerfasserIn  |0 (DE-588)1286859611  |0 (DE-627)1843457032  |4 aut 
700 1 |a Göllner, Stefanie  |d 1979-  |e VerfasserIn  |0 (DE-588)133882764  |0 (DE-627)557870151  |0 (DE-576)300169191  |4 aut 
700 1 |a Kleist, Christian  |e VerfasserIn  |0 (DE-588)138977410  |0 (DE-627)703170287  |0 (DE-576)309272971  |4 aut 
700 1 |a Zhou, Fengbiao  |d 1983-  |e VerfasserIn  |0 (DE-588)1060649128  |0 (DE-627)800416376  |0 (DE-576)416777082  |4 aut 
700 1 |a Rahfeld, Jens-Ulrich  |e VerfasserIn  |4 aut 
700 1 |a Sauer, Tim  |d 1981-  |e VerfasserIn  |0 (DE-588)138282013  |0 (DE-627)601099516  |0 (DE-576)307058166  |4 aut 
700 1 |a Schmitt, Michael  |d 1966-  |e VerfasserIn  |0 (DE-588)133177173  |0 (DE-627)538000600  |0 (DE-576)299672921  |4 aut 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
773 0 8 |i Enthalten in  |t International journal of cancer  |d Bognor Regis : Wiley-Liss, 1966  |g 150(2022), 7, Seite 1141-1155  |h Online-Ressource  |w (DE-627)269532781  |w (DE-600)1474822-8  |w (DE-576)079876129  |x 1097-0215  |7 nnas  |a CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells 
773 1 8 |g volume:150  |g year:2022  |g number:7  |g pages:1141-1155  |g extent:15  |a CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells 
856 4 0 |u https://doi.org/10.1002/ijc.33865  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33865  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20230424 
993 |a Article 
994 |a 2022 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 16  |y j 
998 |g 133177173  |a Schmitt, Michael  |m 133177173:Schmitt, Michael  |d 910000  |d 910100  |e 910000PS133177173  |e 910100PS133177173  |k 0/910000/  |k 1/910000/910100/  |p 15 
998 |g 138282013  |a Sauer, Tim  |m 138282013:Sauer, Tim  |d 910000  |d 910100  |e 910000PS138282013  |e 910100PS138282013  |k 0/910000/  |k 1/910000/910100/  |p 14 
998 |g 1060649128  |a Zhou, Fengbiao  |m 1060649128:Zhou, Fengbiao  |d 910000  |d 910100  |e 910000PZ1060649128  |e 910100PZ1060649128  |k 0/910000/  |k 1/910000/910100/  |p 12 
998 |g 138977410  |a Kleist, Christian  |m 138977410:Kleist, Christian  |d 910000  |d 911400  |e 910000PK138977410  |e 911400PK138977410  |k 0/910000/  |k 1/910000/911400/  |p 11 
998 |g 133882764  |a Göllner, Stefanie  |m 133882764:Göllner, Stefanie  |d 910000  |d 910100  |e 910000PG133882764  |e 910100PG133882764  |k 0/910000/  |k 1/910000/910100/  |p 10 
998 |g 1286859611  |a Schmidt, Christina  |m 1286859611:Schmidt, Christina  |d 50000  |e 50000PS1286859611  |k 0/50000/  |p 9 
998 |g 1190667665  |a Janssen, Maike  |m 1190667665:Janssen, Maike  |d 910000  |d 910100  |e 910000PJ1190667665  |e 910100PJ1190667665  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 1148021574  |a Blank, Maximilian Felix  |m 1148021574:Blank, Maximilian Felix  |d 910000  |d 910100  |e 910000PB1148021574  |e 910100PB1148021574  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 1286858801  |a Yao, Hao  |m 1286858801:Yao, Hao  |d 50000  |e 50000PY1286858801  |k 0/50000/  |p 5 
998 |g 1286858496  |a Lauk, Annika  |m 1286858496:Lauk, Annika  |d 50000  |e 50000PL1286858496  |k 0/50000/  |p 4 
998 |g 1147867631  |a Schubert, Maria-Luisa  |m 1147867631:Schubert, Maria-Luisa  |d 910000  |d 910100  |e 910000PS1147867631  |e 910100PS1147867631  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1164192132  |a Liu, Yi  |m 1164192132:Liu, Yi  |d 910000  |d 910100  |e 910000PL1164192132  |e 910100PL1164192132  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1843457741  |e 4312998442 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Yi Liu, Sanmei Wang, Maria-Luisa Schubert, Annika Lauk, Hao Yao, Maximilian Felix Blank, Chunhong Cui, Maike Janssen, Christina Schmidt, Stefanie Göllner, Christian Kleist, Fengbiao Zhou, Jens-Ulrich Rahfeld, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow"]},"id":{"eki":["1843457741"],"doi":["10.1002/ijc.33865"]},"physDesc":[{"extent":"15 S."}],"recId":"1843457741","origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"person":[{"display":"Liu, Yi","family":"Liu","given":"Yi","role":"aut"},{"role":"aut","given":"Sanmei","family":"Wang","display":"Wang, Sanmei"},{"display":"Schubert, Maria-Luisa","family":"Schubert","given":"Maria-Luisa","role":"aut"},{"display":"Lauk, Annika","family":"Lauk","given":"Annika","role":"aut"},{"display":"Yao, Hao","family":"Yao","role":"aut","given":"Hao"},{"display":"Blank, Maximilian Felix","role":"aut","given":"Maximilian Felix","family":"Blank"},{"display":"Cui, Chunhong","given":"Chunhong","role":"aut","family":"Cui"},{"family":"Janssen","given":"Maike","role":"aut","display":"Janssen, Maike"},{"display":"Schmidt, Christina","given":"Christina","role":"aut","family":"Schmidt"},{"family":"Göllner","role":"aut","given":"Stefanie","display":"Göllner, Stefanie"},{"display":"Kleist, Christian","role":"aut","given":"Christian","family":"Kleist"},{"role":"aut","given":"Fengbiao","family":"Zhou","display":"Zhou, Fengbiao"},{"display":"Rahfeld, Jens-Ulrich","family":"Rahfeld","given":"Jens-Ulrich","role":"aut"},{"given":"Tim","role":"aut","family":"Sauer","display":"Sauer, Tim"},{"family":"Schmitt","role":"aut","given":"Michael","display":"Schmitt, Michael"},{"display":"Müller-Tidow, Carsten","given":"Carsten","role":"aut","family":"Müller-Tidow"}],"relHost":[{"pubHistory":["1.1966 -"],"titleAlt":[{"title":"Predictive oncology"}],"corporate":[{"role":"isb","display":"International Union against Cancer"}],"id":{"zdb":["1474822-8"],"doi":["10.1002/(ISSN)1097-0215"],"issn":["1097-0215"],"eki":["269532781"]},"part":{"pages":"1141-1155","extent":"15","text":"150(2022), 7, Seite 1141-1155","issue":"7","year":"2022","volume":"150"},"recId":"269532781","physDesc":[{"extent":"Online-Ressource"}],"disp":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cellsInternational journal of cancer","titleTranslated":[{"translated":"Journal international du cancer"}],"origin":[{"publisherPlace":"Bognor Regis","dateIssuedKey":"1966","dateIssuedDisp":"1966-","publisher":"Wiley-Liss"}],"title":[{"title":"International journal of cancer","title_sort":"International journal of cancer","subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 28.02.08","Darin: Predictive oncology"]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["First published: 11 November 2021","Gesehen am 24.04.2023"],"title":[{"title_sort":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells"}]} 
SRT |a LIUYIWANGSCD33DIRECT2022